BRIDGEBIO PHARMA INC's ticker is BBIO and the CUSIP is 10806X102. A total of 182 filers reported holding BRIDGEBIO PHARMA INC in Q1 2022. The put-call ratio across all filers is 0.50 and the average weighting 0.3%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q4 2021 | $4,784,000 | -64.2% | 286,837 | +0.5% | 0.00% | -60.0% |
| Q3 2021 | $13,374,000 | -22.6% | 285,332 | +0.6% | 0.01% | -28.6% |
| Q2 2021 | $17,281,000 | -1.3% | 283,490 | -0.2% | 0.01% | 0.0% |
| Q1 2021 | $17,501,000 | -13.4% | 284,099 | +0.0% | 0.01% | -22.2% |
| Q4 2020 | $20,200,000 | +89.9% | 284,069 | +0.2% | 0.01% | +80.0% |
| Q3 2020 | $10,636,000 | +21.6% | 283,485 | +0.1% | 0.01% | 0.0% |
| Q2 2020 | $8,750,000 | +6.5% | 283,300 | 0.0% | 0.01% | 0.0% |
| Q1 2020 | $8,216,000 | -17.3% | 283,300 | 0.0% | 0.01% | 0.0% |
| Q4 2019 | $9,930,000 | +32.1% | 283,300 | -19.1% | 0.01% | +25.0% |
| Q3 2019 | $7,515,000 | -20.4% | 350,000 | 0.0% | 0.00% | -20.0% |
| Q2 2019 | $9,440,000 | – | 350,000 | – | 0.01% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Aisling Capital Management LP | 6,068,125 | $160,016,456 | 65.94% |
| Kohlberg Kravis Roberts & Co. L.P. | 31,060,971 | $819,077,805 | 28.79% |
| Cormorant Asset Management, LP | 4,662,530 | $122,950,916 | 7.17% |
| Frazier Life Sciences Management, L.P. | 2,725,949 | $71,883,275 | 4.77% |
| Octagon Capital Advisors LP | 971,639 | $25,622,120 | 3.94% |
| M28 Capital Management LP | 121,200 | $3,196,044 | 3.66% |
| VIKING GLOBAL INVESTORS LP | 25,120,991 | $662,440,533 | 2.69% |
| BOONE CAPITAL MANAGEMENT LLC | 313,381 | $8,263,857 | 2.61% |
| Fernwood Investment Management, LLC | 235,620 | $6,213,299 | 2.23% |
| SOUTHPORT MANAGEMENT, L.L.C. | 15,000 | $395,550 | 2.15% |